8XB Stock Overview
A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biocartis Group NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.26 |
| 52 Week High | €0.76 |
| 52 Week Low | €0.26 |
| Beta | 1.38 |
| 1 Month Change | 0% |
| 3 Month Change | 1.17% |
| 1 Year Change | -47.09% |
| 3 Year Change | -94.25% |
| 5 Year Change | -97.38% |
| Change since IPO | -98.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8XB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | 0.3% |
| 1Y | -47.1% | -9.1% | 6.9% |
Return vs Industry: 8XB underperformed the German Medical Equipment industry which returned 9.8% over the past year.
Return vs Market: 8XB underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| 8XB volatility | |
|---|---|
| 8XB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8XB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8XB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 526 | Roger Moody | www.biocartisgroupnv.be |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
Biocartis Group NV Fundamentals Summary
| 8XB fundamental statistics | |
|---|---|
| Market cap | €27.24m |
| Earnings (TTM) | -€67.87m |
| Revenue (TTM) | €60.82m |
0.4x
P/S Ratio-0.4x
P/E RatioIs 8XB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8XB income statement (TTM) | |
|---|---|
| Revenue | €60.82m |
| Cost of Revenue | €65.51m |
| Gross Profit | -€4.69m |
| Other Expenses | €63.18m |
| Earnings | -€67.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -7.71% |
| Net Profit Margin | -111.58% |
| Debt/Equity Ratio | -257.9% |
How did 8XB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/23 20:31 |
| End of Day Share Price | 2023/09/25 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocartis Group NV is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Bardo | Berenberg |
| Hugo Solvet | Bryan Garnier & Co |
| Guy Sips | KBC Securities NV |